uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine
Show others and affiliations
2014 (English)In: Vaccine, ISSN 0264-410X, E-ISSN 1873-2518, Vol. 32, no 43, 5614-5623 p.Article in journal (Refereed) Published
Abstract [en]

Vaccines used against seasonal influenza are poorly effective against influenza A viruses of novel subtypes that may have pandemic potential. Furthermore, pre(pandemic) influenza vaccines are poorly immunogenic, which can be overcome by the use of adjuvants. A limited number of adjuvants has been approved for use in humans, however there is a need for alternative safe and effective adjuvants that can enhance the immunogenicity of influenza vaccines and that promote the induction of broad-protective T cell responses. Here we evaluated a novel nanoparticle, G3, as an adjuvant for a seasonal trivalent inactivated influenza vaccine in a mouse model. The G3 adjuvant was formulated with or without steviol glycosides (DT, for diterpenoid). The use of both formulations enhanced the virus-specific antibody response to all three vaccine strains considerably. The adjuvants were well tolerated without any signs of discomfort. To assess the protective potential of the vaccine-induced immune responses, an antigenically distinct influenza virus strain, A/Puerto Rico/8/34 (A/PR/8/34), was used for challenge infection. The vaccine-induced antibodies did not cross-react with strain A/PR/8/34 in HI and VN assays. However, mice immunized with the G3/DT-adjuvanted vaccine were partially protected against A/PR/8/34 infection, which correlated with the induction of anamnestic virus-specific CD8(+) T cell responses that were not observed with the use of G3 without DT. Both formulations induced maturation of human dendritic cells and promoted antigen presentation to a similar extent. In conclusion, G3/DT is a promising adjuvant formulation that not only potentiates the antibody response induced by influenza vaccines, but also induces T cell immunity which could afford broader protection against antigenically distinct influenza viruses.

Place, publisher, year, edition, pages
2014. Vol. 32, no 43, 5614-5623 p.
Keyword [en]
Adjuvant, Split virion vaccine, T cells, Heterosubtypic immunity
National Category
Immunology in the medical area
URN: urn:nbn:se:uu:diva-240958DOI: 10.1016/j.vaccine.2014.08.003ISI: 000343638200014OAI: oai:DiVA.org:uu-240958DiVA: diva2:777502
Available from: 2015-01-08 Created: 2015-01-08 Last updated: 2015-01-08Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Infectious Diseases
In the same journal
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 174 hits
ReferencesLink to record
Permanent link

Direct link